The role of weekly docetaxel in the treatment of advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 3, Issue SUPPL. 2, 2002, Pages

  Hainsworth, John D ^a   Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Combination therapy; Elderly patient; Myelosuppression; Toxicity; Weekly schedule

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA;

EID: 0036300740     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2002.s.009     Document Type: Article

References (33)

1. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer
2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
3. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
4. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer
5. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non small cell lung cancer (NSCLC). A preliminary analysis
6. Vinorelbine and gemcitabine combinations in advanced non-small-cell lung cancer
7. Irinotecan and taxane combinations for non-small-cell lung cancer
8. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer
9. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer
10. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
11. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
12. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
13. Weekly docetaxel treatment in metastatic breast cancer: A phase I/II study
14. Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results
15. Phase I study of docetaxel with concomitant thoracic radiation therapy
16. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial
17. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial
18. A phase II trial of weekly taxotere as first line chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC)
19. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
20. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
21. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma
22. Second-line therapy with weekly docetaxel in resistant or relapsed non-small cell lung cancer (NSCLC): Final results
23. A phase II study of weekly docetaxel in previously treated patients with non-small-cell lung cancer (NSCLC)
24. Early phase II of docetaxel in second line of advanced non small cell lung cancer (NSCLC): Preliminary results
25. Phase II study of weekly docetaxel as second-line chemotherapy in patients with unresectable or metastatic non-small cell lung cancer
26. Gemcitabine (GEM) as a single agent in the treatment of elderly (=70 years) patients with stage III-IV non-small cell lung cancer (NSCLC) as compared to those <70 years old
27. Weekly docetaxel/gemcitabine in the treatment of elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): A Minnie Pearl Cancer Research Network Phase II Trial
28. Phase-II trial of weekly docetaxel (Taxotere) plus gemcitabine (Gemzar) as first-line therapy for patients (pts) with advanced non-small cell lung cancer (ANSCLC)
29. A phase II study of a combination of docetaxel and gemcitabine in a weekly schedule as first line treatment in stages IIIB/IV non-small-cell lung cancer (NSCLC)
30. A phase I study of docetaxel (D) and gemcitabine (G) in advanced non-small cell lung cancer
31. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: Gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients
32. Phase II trial of weekly docetaxel and vinorelbine in patients with relapsed non-small cell lung cancer (NSCLC)
33. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network